XPhyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide a look at their German subsidiary, Vektor Pharma who is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients.
Rogers telling Proactive the program is on track and a European human study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021.
Price: 3.15 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
XPhyto Therapeutics (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive with news the company has received the first purchases of their 25 minute rapid PCR test which is being manufactured in Germany. These tests will be used for regulatory approvals in a number...
Industry & services
Retail & consumer
Prev article
